Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Armin Foghi

Vascular Surgery Victorville, CA Medical Doctor

NPI 1952358376 CMS profile 760839

15095 Amargosa Rd, Victorville, CA 92394

Open in the dashboard

General payments

$36,435

125 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Armin Foghi of Victorville, CA is reported in the CMS Open Payments database as having received $36,435 across 125 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,273 26
2024 General $1,249 8
2023 General $278 14
2022 General $2,169 39
2021 General $4,361 11
2020 General $1,118 4
2019 General $21,988 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Armin Foghi
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Armin Foghi were reported at $5,273. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Armin Foghi Vascular Surgery median Middle half National median
2019 $21,988 $796 $226–$2,363 $163
2020 $1,118 $348 $118–$1,110 $114
2021 $4,361 $471 $158–$1,421 $132
2022 $2,169 $725 $222–$2,183 $149
2023 $278 $836 $257–$2,440 $160
2024 $1,249 $909 $252–$2,619 $164
2025 $5,273 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biocompatibles, Inc. $21,760 13 payments
  2. AngioDynamics, Inc. $9,102 11 payments
  3. Tactile Systems Technology Inc $4,507 70 payments
  4. Bard Peripheral Vascular, Inc. $293 3 payments
  5. Advanced Oxygen Therapy Inc. $158 4 payments
  6. Medtronic, Inc. $144 5 payments
  7. Janssen Pharmaceuticals, Inc $130 6 payments
  8. Boston Scientific Corporation $106 5 payments
  9. AstraZeneca Pharmaceuticals LP $92 2 payments
  10. Medicomp Inc $54 1 payment
  11. Other $89 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $19,000 3 payments
  2. Consulting Fee $4,850 3 payments
  3. Food and Beverage $3,389 110 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,925 1 payment
  5. Education $2,391 3 payments
  6. Travel and Lodging $1,961 3 payments
  7. Long term medical supply or device loan $1,920 2 payments
Products named General payments · program years 2019–2025
  1. VARITHENA $21,760 13 payments
  2. Flexitouch Plus $4,416 64 payments
  3. Nimbl $3,870 17 payments
  4. VenaCure 1470 Pro Endovascular Therapies $2,800 1 payment
  5. VenaCure 1470 Pro Et $2,248 3 payments
  6. VenaCure 1470 Pro Vit $1,983 4 payments
  7. EVLT $1,076 1 payment
  8. VenaCure 1470 Pro Id $960 1 payment
  9. Entre Plus $351 14 payments
  10. Venclose Maven Catheter $293 3 payments
  11. Other $1,239 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Cardiology: 2,533

Drug cost

$199

Median for Cardiology: $485,213

Branded share of claims

0%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 11 $199

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$1,060,762

Medicare's payments for the services billed

Medicare patients

326

Average age 75

Services billed

3,047

215 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 58%
Chronic kidney disease 26%
Diabetes 25%
Ischemic heart disease 22%
Depression 21%
Osteoporosis 19%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

125 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record